| |
| |
|
| Insider
Information: |
Reddoch James F. |
| Relationship: |
EVP & Chief Scientific... |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
845,830 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$23,920,072 |
|
|
| Total
Shares |
845,830 |
|
|
| Total
Value |
$23,920,072 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Royalty Pharma Plc |
RPRX |
EVP & Chief Scientific... |
2020-06-18 |
0 |
2022-09-28 |
845,830 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
22 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RPRX |
Royalty Pharma Plc |
EVP & Chief Scientific Officer |
• – – |
2022-09-28 |
4 |
S |
$41.23 |
$4,122,670 |
I/I |
(100,000) |
820,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP & Chief Scientific Officer |
• – – |
2022-06-08 |
4 |
S |
$41.56 |
$4,155,900 |
I/I |
(100,000) |
920,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP & Chief Scientific Officer |
• – – |
2022-05-27 |
4 |
S |
$41.08 |
$3,081,008 |
I/I |
(75,000) |
1,020,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP & Chief Scientific Officer |
• – – |
2022-05-19 |
4 |
S |
$40.44 |
$3,033,128 |
I/I |
(75,000) |
1,095,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-26 |
4 |
S |
$39.78 |
$355,977 |
I/I |
(8,949) |
1,170,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-14 |
4 |
S |
$42.00 |
$84 |
I/I |
(2) |
1,179,749 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-13 |
4 |
S |
$42.01 |
$749,081 |
I/I |
(17,832) |
1,179,751 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-12 |
4 |
S |
$42.04 |
$4,204 |
I/I |
(100) |
1,197,583 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-08 |
4 |
S |
$42.05 |
$1,709,380 |
I/I |
(40,655) |
1,197,683 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-07 |
4 |
S |
$42.01 |
$92,087 |
I/I |
(2,192) |
1,238,338 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-07-06 |
4 |
S |
$42.40 |
$1,283,560 |
I/I |
(30,270) |
1,240,530 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-06-08 |
4 |
AS |
$46.43 |
$2,321,540 |
I/I |
(50,000) |
1,270,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-06-07 |
4 |
AS |
$46.57 |
$2,329,419 |
I/I |
(50,000) |
1,320,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-06-04 |
4 |
AS |
$44.60 |
$4,459,730 |
I/I |
(100,000) |
1,370,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-06-02 |
4 |
S |
$42.13 |
$2,106,560 |
I/I |
(50,000) |
1,470,800 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
I/I |
1,320,800 |
1,520,800 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-04-14 |
4 |
S |
$42.10 |
$2,345,593 |
I/I |
(55,714) |
200,000 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-04-12 |
4 |
S |
$42.32 |
$15,193 |
I/I |
(359) |
255,714 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-03-22 |
4 |
S |
$46.32 |
$2,034,519 |
I/I |
(43,927) |
256,073 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2021-03-02 |
4 |
S |
$46.89 |
$4,692,158 |
I/I |
(100,000) |
300,000 |
0 |
% |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2020-12-31 |
4 |
A |
$0.00 |
$0 |
I/I |
400,000 |
400,000 |
0 |
- |
|
| RPRX |
Royalty Pharma Plc |
EVP, Research & Investments |
• – – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
I/I |
25,030 |
25,030 |
0 |
- |
|
22 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
